Population pharmacokinetic modeling of glibenclamide in poorly controlled South African type 2 diabetic subjects
Virendra Rambiritch,1 Poobalan Naidoo,2 Breminand Maharaj,1 Goonaseelan Pillai3 1University of KwaZulu-Natal, Durban, 2Department of Internal Medicine, RK Khan Regional Hospital, Chatsworth, South Africa; 3Novartis Pharma AG, Basel, Switzerland Aim: The aim of this study was to describe th...
Guardado en:
Autores principales: | Rambiritch V, Naidoo P, Maharaj B, Pillai G |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1308fa1e06f2436498108381527c0a04 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects
por: Rambiritch V, et al.
Publicado: (2016) -
Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study
por: Rambiritch V, et al.
Publicado: (2014) -
Glibenclamide therapy: pros and cons
por: Olga Konstantinovna Vikulova, et al.
Publicado: (2011) -
A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
por: Gellért Balázs Karvaly, et al.
Publicado: (2021) -
Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies
por: Li Y, et al.
Publicado: (2020)